CYP3A4 and cancer: Thus, if combined with chemo-therapeutic drugs metabolized by CYP3A4, hyperforin would greatly reduce the efficacy of a potential anti-cancer combination therapy approach since it accelerates metabolization of the drug(s) it is combined with.